What caused the pre‑market drop in ALVIO.PA stock?

The fall to **€0.107** pre‑market on 19 Mar 2026 was volume‑driven, with heavy selling versus avg volume **401,720**, amid sector weakness and no immediate positive catalyst. Clinical and funding concerns often trigger outsized moves in biotech stocks.

What is Meyka AI’s outlook and forecast for ALVIO.PA stock?

Meyka AI's forecast model projects monthly **€0.16**, quarterly **€0.21** and yearly **€0.270264** for ALVIO.PA stock. The yearly target implies a **152.64%** upside from **€0.107**; forecasts are model projections and not guarantees.

Is ALVIO.PA stock a buy after the drop?

Meyka AI assigns ALVIO.PA a **B+ (70.85)** grade with a BUY suggestion, balancing clinical potential and valuation risks. This is informational only; consider cash runway, EPS **-0.09**, and trial timelines before acting.

EU Stocks

ALVIO.PA stock down 18.94% pre-market 19 Mar 2026: €0.107 test and what to watch next

ByDanny Kontos March 19, 2026

ALVIO.PA stock opened the pre-market session on EURONEXT down -18.94%, trading at €0.107 on 19 Mar 2026 after an intraday low of €0.1025. The sharp move follows heavy volume at 1,112,894 shares versus a 30‑day average of 401,720, signalling active selling in the biotechnology sector in Europe. Valerio Therapeutics SA (ALVIO.PA) reports negative earnings per share of -0.09 and a trailing PE of -1.19, underlining continued clinical‑stage cash burn. We review drivers, technicals, valuation and Meyka AI’s model forecast to frame near‑term risks and possible support levels.